Table 2.
Glycemic Performance of USS Virginia Hybrid Closed-Loop Control Versus Sensor-Augmented Pump Therapy
| USS Virginia HCLC | SAP | Relative improvement post vs. pre | ||||
|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | F | P | |
| LBGI | 2.51 ± 1.17 | 1.28 ± 0.5 | 2.1 ± 1.05 | 1.79 ± 0.98 | 15.2 | <0.001 |
| Percent below 54 mg/dL (3.0 mmol/L) | 2.1% ± 2.2% | 0.3% ± 0.4% | 1.3% ± 1.8% | 0.9% ± 1.1% | 5.8 | 0.02 |
| Percent below 60 mg/dL (3.3 mmol/L) | 3.4% ± 3.3% | 0.8% ± 0.7% | 2.6% ± 2.8% | 2.1% ± 2.5% | 8.5 | 0.006 |
| Percent below 70 mg/dL (3.9 mmol/L) | 7.2% ± 5.3% | 2% ± 1.4% | 5.8% ± 4.7% | 4.8% ± 4.5% | 11.8 | 0.001 |
| Percent between 70–180 mg/dL (3.9–10 mmol/L) | 67.8% ± 13.5% | 78.2% ± 10% | 65.6% ± 12.9% | 59.6% ± 16.5% | 14.8 | <0.001 |
| Percent above 180 mg/dL (10 mmol/L) | 25.1% ± 15.3% | 19.8% ± 10.1% | 28.6% ± 14.6% | 35.6% ± 17.6% | 7.5 | 0.009 |
| Percent above 250 mg/dL (13.9 mmol/L) | 6.8% ± 9.8% | 3.6% ± 3.9% | 8.5% ± 8.1% | 11.2% ± 9.4% | 5.5 | 0.024 |
| Percent above 300 mg/dL (16.7 mmol/L) | 2.5% ± 4.8% | 1.1% ± 1.8% | 2.7% ± 3.3% | 3.6% ± 5.6% | 3.3 | 0.077 |
| Mean glucose mg/dL (mmol/L) | 144.9 ± 27.9 (8.1 ± 1.6) | 143.8 ± 14.4 (8.0 ± 0.8) | 152.5 ± 24.3 (8.5 ± 1.4) | 162.4 ± 28.2 (9.0 ± 1.6) | 2.2 | ns |
| Glucose variability (coefficient of variation) | 0.38 ± 0.06 | 0.32 ± 0.04 | 0.38 ± 0.05 | 0.37 ± 0.07 | 7.1 | 0.011 |
| High blood glucose index | 5.7 ± 4.1 | 4.5 ± 2.1 | 6.6 ± 3.6 | 8.1 ± 4.3 | 6.1 | 0.018 |
| ADRR | 8.1 ± 3.6 | 6.2 ± 2.6 | 7.9 ± 2.3 | 8.1 ± 3.4 | 2.8 | 0.102 |
| Daytime (7 am–11 pm) | ||||||
| LBGI | 2.55 ± 1.07 | 1.28 ± 0.51 | 1.92 ± 0.98 | 1.72 ± 1.03 | 21.6 | <0.001 |
| Percent below 54 mg/dL (3.0 mmol/L) | 1.8% ± 1.8% | 0.3% ± 0.4% | 1.1% ± 1.3% | 0.9% ± 1.3% | 9.8 | 0.003 |
| Percent below 60 mg/dL (3.3 mmol/L) | 3.4% ± 2.8% | 0.8% ± 0.7% | 2.2% ± 2.3% | 2.1% ± 2.5% | 15.2 | <0.001 |
| Percent below 70 mg/dL (3.9 mmol/L) | 7.4% ± 5% | 2.1% ± 1.6% | 5.1% ± 4.2% | 4.7% ± 4.3% | 19.1 | <0.001 |
| Percent between 70–180 mg/dL (3.9–10 mmol/L) | 69.2% ± 12.5% | 77.9% ± 11% | 66.1% ± 12.9% | 59.3% ± 15.7% | 12.3 | 0.001 |
| Percent above 180 mg/dL (10 mmol/L) | 23.3% ± 14.1% | 20% ± 11.1% | 28.8% ± 14.6% | 36% ± 16.8% | 5.8 | 0.020 |
| Percent above 250 mg/dL (13.9 mmol/L) | 6.8% ± 9.7% | 3.5% ± 3.3% | 7.2% ± 6.9% | 11.3% ± 9.1% | 9.8 | 0.003 |
| Percent above 300 mg/dL (16.7 mmol/L) | 2.5% ± 4.6% | 1% ± 1.6% | 1.6% ± 2.1% | 4% ± 5.8% | 9.0 | 0.005 |
| Mean glucose mg/dL (mmol/L) | 142.9 ± 26.9 (7.9 ± 1.5) | 144.1 ± 15.5 (8.0 ± 0.9) | 152.2 ± 22.5 (8.5 ± 1.3) | 163.9 ± 27 (9.1 ± 1.5) | 2.3 | ns |
| Glucose variability (coefficient of variation) | 0.38 ± 0.05 | 0.32 ± 0.04 | 0.36 ± 0.05 | 0.37 ± 0.08 | 15.3 | <0.001 |
| High blood glucose index | 5.5 ± 4 | 4.5 ± 2.1 | 6.3 ± 3.2 | 8.3 ± 4.2 | 7.8 | 0.008 |
| Overnight (11 pm–7 am) | ||||||
| LBGI | 2.34 ± 1.79 | 1.23 ± 0.71 | 2.34 ± 1.51 | 1.87 ± 1.12 | 2 | ns |
| Percent below 54 mg/dL (3.0 mmol/L) | 2.5% ± 3.9% | 0.4% ± 0.5% | 1.9% ± 3.2% | 0.8% ± 1.1% | 1.5 | ns |
| Percent below 60 mg/dL (3.3 mmol/L) | 3.5% ± 5% | 0.8% ± 1.2% | 3.4% ± 4.4% | 2.2% ± 3.1% | 1.4 | ns |
| Percent below 70 mg/dL (3.9 mmol/L) | 6.6% ± 7.4% | 1.9% ± 2.3% | 7.2% ± 6.6% | 5.3% ± 6.1% | 2.0 | ns |
| Percent between 70–180 mg/dL (3.9–10 mmol/L) | 64.9% ± 19.1% | 78.7% ± 12.6% | 64.5% ± 16.6% | 60% ± 22% | 8.4 | 0.006 |
| Percent above 180 mg/dL (10 mmol/L) | 28.5% ± 21.7% | 19.4% ± 12.6% | 28.3% ± 18.8% | 34.7% ± 23.4% | 4.8 | 0.034 |
| Percent above 250 mg/dL (13.9 mmol/L) | 6.7% ± 10.7% | 3.7% ± 6.1% | 10.8% ± 11.7% | 10.9% ± 12.1% | 0.7 | ns |
| Percent above 300 mg/dL (16.7 mmol/L) | 2.4% ± 5.4% | 1.3% ± 3.3% | 4.7% ± 6.1% | 2.6% ± 6.1% | 0.3 | ns |
| Mean glucose mg/dL (mmol/L) | 148.9 ± 34.2 (8.3 ± 1.9) | 143.5 ± 19.3 (8.0 ± 1.1) | 153.3 ± 32.5 (8.5 ± 1.8) | 159.2 ± 35.3 (8.8 ± 2.0) | 1.1 | ns |
| Glucose variability (coefficient of variation) | 0.34 ± 0.09 | 0.31 ± 0.06 | 0.38 ± 0.08 | 0.34 ± 0.06 | 0.3 | ns |
| High blood glucose index | 6.2 ± 4.9 | 4.4 ± 2.9 | 7.1 ± 4.9 | 7.6 ± 5.4 | 2.1 | ns |
Values are reported as mean ± SD. The repeated-measures general linear model was used to compare HCLC versus SAP data collected during the baseline week (pre) versus the last week of study (post).
ADRR, average daily risk range; HCLC, hybrid closed-loop control.